GlassScriptPhysician profile
Sara B Ahmed
NPI 1679732507
$3,683.76
in general payments reported to CMS, 2019-2025
24 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.91 · 2020: $434 · 2021: $183 · 2022: $827 · 2023: $997 · 2024: $596 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Travel and Lodging: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.01 |
| Travel and Lodging | $428.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,023.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $625.05 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Abiomed | $588.40 | 2022-2023 | Impella |
| Philips North America LLC | $462.34 | 2020-2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $271.12 | 2021-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.66 | 2020-2023 | Spiriva Respimat |
| Boston Scientific Corporation | $64.63 | 2020-2022 | |
| Pfizer INC. | $57.48 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $53.89 | 2020 | |
| Genentech USA, INC. | $45.33 | 2021-2022 | |
| Advanced Respiratory, INC | $37.32 | 2020 | |
| Insmed, INC. | $31.99 | 2025 | Arikayce |
| Novo Nordisk INC | $30.76 | 2019 | |
| Genzyme Corporation | $22.88 | 2024 | |
| Mylan Specialty L.P. | $22.35 | 2023 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $22.17 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Jazz Pharmaceuticals INC. | $19.68 | 2020 | |
| Exact Sciences Corporation | $18.83 | 2023 | Cologuard Collection Kit |
| Verona Pharma, INC. | $18.59 | 2025 | Ohtuvayre |
| Allergan, INC. | $17.78 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $16.77 | 2024 | Opsumit |
| Mallinckrodt Hospital Products INC. | $15.77 | 2024 | Acthar |
| Electromed, INC. | $13.91 | 2025 | Smartvest |
| Lilly USA, LLC | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.